Disposition of perfluorobutane in rats after intravenous injection of Sonazoid™

Toft, Kim Gunnar; Hustvedt, Svein Olaf; Hals, Petter‐Arnt; Oulie, Inger; Uran, Steinar; Landmark, Kristin Eitrem; Normann, Per T.; Skotland, Tore

doi:10.1016/j.ultrasmedbio.2005.09.008

Cited by 55 publications

(37 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although Sonazoid TM is known to be captured by the reticulo-endothelial system, after intravenous injection almost all of it remains entirely within the intravascular space without being trapped in normal small vessels. 11,[14][15][16] Furthermore, Sonazoid TM is rheologically similar to red blood cells. These characteristics of Sonazoid TM in renal CEUS imaging enable prolonged visualization of blood flow in the renal arterioles and capillaries, as demonstrated in this study.…”

Section: Discussionmentioning

confidence: 97%

Evaluation of Renal Microcirculation by Contrast-Enhanced Ultrasound With SonazoidTM as a Contrast Agent Comparison Between Normal Subjects and Patients With Chronic Kidney Disease

et al. 2010

View full text Add to dashboard Cite

SummaryChronic kidney disease (CKD) is a major and serious risk factor for cardiovascular disease (CVD). Continuous hypoxia due to hypoperfusion in peritubular capillaries is one of the factors aggravating CKD, but evaluation of perfusion in this region is difficult using clinically available imaging methods. Since the second-generation ultrasound contrast agent Sonazoid TM has a stable shell, it enables visualization of the renal vasculature for a long period of time. We therefore evaluated changes in contrast-enhanced ultrasound (CEUS) imaging with Sonazoid TM in CKD patients.Sonazoid TM was used in 85 CKD patients and 5 control subjects, and images were recorded for 10 minutes. Time-intensity curves were generated from the images of 62 time points in both cortex and medulla.In control samples, contrast enhancement spread from the hilar portion to the periphery along the direction of arterial flow, and renal cortex and medulla were then enhanced in sequence. Enhancement was maximal soon after, then gradually decreased, but was still visible at 600 seconds. In CKD patients, renal contrast enhancement was attenuated in both cortex and medulla. On time-intensity curves, the attenuation of enhancement was composed of delayed rising, reduction of peak, and acceleration of decay in both cortex and medulla with progression of renal dysfunction. No side effects of the contrast agent were observed in any subjects.The attenuation of renal contrast enhancement observed in CKD patients appears to reflect disturbance of perfusion in peritubular capillaries. CEUS with Sonazoid TM is a useful and safe means of visualizing the renal microvasculature. (Int Heart J 2010; 51: 176-182)

show abstract

Section: Discussionmentioning

confidence: 97%

Evaluation of Renal Microcirculation by Contrast-Enhanced Ultrasound With SonazoidTM as a Contrast Agent Comparison Between Normal Subjects and Patients With Chronic Kidney Disease

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Levovist ® CEUS provides information on both the blood flow and the parenchyma through the characteristics of the contrast agent [20,21] . Microbubbles injected via the intravenous route travel through the blood vessels, producing vascular images, and the gas is finally eliminated through the lungs [22] . However, some kinds of microbubbles accumulate in the organs such as the liver [23] and the spleen [24] , which allows delayed phase imaging [25] .…”

Section: Discussionmentioning

confidence: 99%

Decreased phagocytic activity of Kupffer cells in a rat nonalcoholic steatohepatitis model

Tsujimoto¹,

Kawaratani²,

Kitazawa³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…With the development of second UCAs (Sonovue ® and Sonazoid ® ) which contain inert gases with low solubility in water, the stability and duration of the contrast and real-time vascular images have been increased. The risk for drug allergy is small because of the small molecular weight of microbubbles and they are also applicable for patients with liver and renal dysfunctions because it is excreted by exhalation [51,52] . Most carcinomas, neuroendocrine tumors and inflammatory pseudotumors are simply depicted as hypoechoic masses, but the use of contrast agents in EUS has been shown to improve the characterization of the vasculature inside the organ of interest, to better delineate such hypoechoic masses.…”

Section: Contrast-enhanced Eus (Ceh-eus) Is Performedmentioning

confidence: 99%

Role of endoscopic ultrasound in the diagnosis of pancreatic cancer

Gonzalo-Marin¹

2014

WJGO

View full text Add to dashboard Cite

Endoscopic ultrasonography (EUS) with or without fine needle aspiration has become the main technique for evaluating pancreatobiliary disorders and has proved to have a higher diagnostic yield than positron emission tomography, computed tomography (CT) and transabdominal ultrasound for recognising early pancreatic tumors. As a diagnostic modality for pancreatic cancer, EUS has proved rates higher than 90%, especially for lesions less than 2-3 cm in size in which it reaches a sensitivity rate of 99% vs 55% for CT. Besides, EUS has a very high negative predictive value and thus EUS can reliably exclude pancreatic cancer. The complication rate of EUS is as low as 1.1%-3.0%. New technical developments such as elastography and the use of contrast agents have recently been applied to EUS, improving its diagnostic capability. EUS has been found to be superior to the recent multidetector CT for T staging with less risk of overstaying in comparison to both CT and magnetic resonance imaging, so that patients are not being ruled out of a potentially beneficial resection. The accuracy for N staging with EUS is 64%-82%. In unresectable cancers, EUS also plays a therapeutic role by means of treating oncological pain through celiac plexus block, biliary drainage in obstructive jaundice in patients where endoscopic retrograde cholangiopancreatography is not affordable and aiding radiotherapy and chemotherapy. Key words: Endosonography; Pancreatic neoplasms; Endoscopy; Diagnosis; Neoplasm Staging; Therapeutics Core tip: In this article, the role of endoscopic ultrasonography as a diagnostic, staging and therapeutic procedure in patients with pancreatic cancer is discussed and all the current knowledge on this subject is summarized, providing the reader with a quick update.Gonzalo-Marin J, Vila JJ, Perez-Miranda M. Role of endoscopic ultrasound in the diagnosis of pancreatic cancer. World J Gastrointest Oncol 2014; 6(9): 360-368 Available from: URL:

show abstract

Disposition of perfluorobutane in rats after intravenous injection of Sonazoid™

Cited by 55 publications

References 17 publications

Evaluation of Renal Microcirculation by Contrast-Enhanced Ultrasound With SonazoidTM as a Contrast Agent Comparison Between Normal Subjects and Patients With Chronic Kidney Disease

Evaluation of Renal Microcirculation by Contrast-Enhanced Ultrasound With SonazoidTM as a Contrast Agent Comparison Between Normal Subjects and Patients With Chronic Kidney Disease

Decreased phagocytic activity of Kupffer cells in a rat nonalcoholic steatohepatitis model

Role of endoscopic ultrasound in the diagnosis of pancreatic cancer

Contact Info

Product

Resources

About